High Court Won't Hear Orexigen Securities Fraud Suit
By Reenat Sinay ( May 20, 2019, 2:43 PM EDT) -- The U.S. Supreme Court declined on Monday to hear a challenge to a Ninth Circuit ruling that biotechnology company Orexigen had a duty to warn investors when new information about a drug conflicted with prior findings that were accurate when disclosed....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.